Polyvascular disease is associated with high risks of major adverse cardiovascular events and death despite intensive statin therapy.
Suboptimal responders have increased risk for incident cardiovascular disease
The addition of monthly evolocumab to statin therapy for individuals with hypercholesterolemia or mixed dyslipidemia and type 2 diabetes led to significant reductions in low-density lipoprotein cholesterol.
Objective short sleep duration is associated with daytime sleepiness, whereas obstructive sleep apnea is associated with obesity, dyslipidemia, and hypertension.
This post hoc analysis is the first to suggest that evolocumab increases the apolipoprotein A1 remnant ratio following 12 weeks of treatment.
People living with HIV and declining cognition exhibit hyperinsulinemia, as well as abnormal cholesterol and lipid metabolism.
There is an opportunity to increase statin use by improving physician recognition of statin-eligible patients.
Lipid-lowering was associated with an increased risk for stroke in secondary prevention trials alone.
Amarin has submitted a supplemental New Drug Application (sNDA) for Vascepa (icosapent ethyl) to reduce the risk of major cardiovascular (CV) events in the statin-treated population. Icosapent ethyl is a single-molecule consisting of the omega-3 acid commonly known as EPA in ethyl-ester form. It is currently indicated as an adjunct to diet to reduce triglyceride…
Investigators conducted a prespecified analyses to evaluate the extent to which icosapent ethyl decreases total ischemic events.
Bempedoic acid, an investigational ATP citrate lyase inhibitor, might safely lower low-density lipoprotein cholesterol levels when added to statin therapy.